Please assess the completion status of the following clinical trial:

Trial Title: Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Females ≥ 18 years of age and \< 65 years.~2. Unilateral or bilateral primary carcinoma of the breast confirmed.~3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2.~4. Clinically measurable tumor size who are candidates for neoadjuvant therapy.~5. No evidence of distant metastasis.~6. Normal renal and liver functions.~7. Non-diabetics.~Exclusion Criteria:~1. Pregnant or breastfeeding women.~2. Prior cancer chemotherapy.~3. Heart disease or reduced cardiac output with left ventricular ejection fraction \< 50%.~4. Metastatic breast cancer patients.~5. Patients with hepatic impairment.~6. Patients with renal impairment.~7. Diabetics.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Metformin group (Type: EXPERIMENTAL): Patients will receive AC-T neoadjuvant chemotherapy in addition to oral metformin HCl (850 mg tablets, twice per day, for 6 months) (n= 30)
- Control group (Type: ACTIVE_COMPARATOR): Patients will receive AC-T neoadjuvant chemotherapy alone (n= 30)

Based on this trial design, predict the completion outcome and termination type (if applicable).